Top

Published in:

Open Access 01-06-2011 | Laboratory Investigation - Human/Animal Tissue

Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells

Authors: Fang Yu, Samuel S. M. Ng, Billy K. C. Chow, Johnny Sze, Gang Lu, Wai Sang Poon, Hsiang-Fu Kung, Marie C. M. Lin

Published in: Journal of Neuro-Oncology | Issue 2/2011

Abstract

Interferon-induced transmembrane protein 1 (IFITM1) has recently been identified as a new molecular marker in human colorectal cancer. However, its role in glioma carcinogenesis is not known. In this study, we demonstrated that suppression of IFITM1 expression significantly inhibited proliferation of glioma cells in a time-dependent manner. The growth inhibitory effect was mediated by cell cycle arrest. Furthermore, IFITM1 knockdown significantly inhibited migration and invasion of glioma cells, which could be attributed to decreased expression and enzymatic activity of matrix metalloproteinase 9. Taken together, these results suggest that IFITM1 is a potential therapeutic target for gliomas.

Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109:93–108. doi:10.1007/s00401-005-0991-y PubMedCrossRef

Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DM, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Gene Dev 15:1311–1333. doi:10.1101/gad.891601 PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987–996PubMedCrossRef

Lewin AR, Reid LE, Mcmahon M, Stark GR, Kerr IM (1991) Molecular analysis of a human interferon-inducible gene family. Eur J Biochem 199:417–423. doi:10.1111/j.1432-1033.1991.tb16139.x PubMedCrossRef

Sato S, Miller A, Howard M, Tedder T (1997) Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 complex requires the cytoplasmic domain of CD19. J Immunol 159:3278–3287PubMed

Tanaka SS, Yamaguchi YL, Tsoi B, Lickert H, Tam PPL (2005) IFITM/mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Dev Cell 9:745–756. doi:10.1016/j.devcel.2005.10.010 PubMedCrossRef

Wylie C (2005) IFITM1-mediated cell repulsion controls the initial steps of germ cell migration in the mouse. Dev Cell 9:723–724. doi:10.1016/j.devcel.2005.11.009 PubMedCrossRef

Yang Y, Lee JH, Kim KY, Song HK, Kim JK, Yoon SR, Cho D, Song KS, Lee YH, Choi I (2005) The interferon-inducible 9–27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer Lett 221:191–200. doi:10.1016/j.canlet.2004.08.022 PubMedCrossRef

Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y, Takata T (2008) IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res 14:6097–6105. doi:10.1158/1078-0432.CCR-07-4761 PubMedCrossRef

10.

Seyfried NT, Huysentruy LC, Atwood JA, Xia QW, Seyfried TN, Orlando R (2008) Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. Cancer Lett 263:243–252. doi:10.1016/j.canlet.2008.01.007 PubMedCrossRef

11.

Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, Kahn A, Perret C, Romagnolo A (2006) Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 66:1949–1955. doi:10.1158/0008-5472.CAN-05-2731 PubMedCrossRef

12.

Pan Z, Chen S, Pan X, Wang Z, Han H, Zheng W, Wang X, Li F, Qu S, Shao R (2010) Differential gene expression identified in Uigur women cervical squamous cell carcinoma by suppression subtractive hybridization. Neoplasma 57:123–128. doi:10.4149/neo_2010_02_123 PubMedCrossRef

13.

Chattopadhyay I, Phukan R, Singh A, Vasudevan M, Purkayastha J, Hewitt S, Kataki A, Mahanta J, Kapur S, Saxena S (2009) Molecular profiling to identify molecular mechanism in esophageal cancer with familial clustering. Oncol Rep 21:1135–1146. doi:10.3892/or_00000333 PubMed

14.

Gyorffy B, Dietel M, Fekete T, Lage H (2008) A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int J Gynecol Cancer 18:1215–1233. doi:10.1111/j.1525-1438.2007.01169.x PubMedCrossRef

15.

Gomez Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WKA (1996) Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56:694–699PubMed

16.

Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331. doi:10.1016/s0092-8674(00)81871-1 PubMedCrossRef

17.

Wang XW, Zhan QM, Coursen JD, Khan MA, Kontny HU, Yu LJ, Hollander MC, O’Connor PM, Fornace AJ, Harris CC (1999) GADD45 induction of a G(2)/M cell cycle checkpoint. Proc Natl Acad Sci USA 96:3706–3711PubMedCrossRef

18.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed

19.

Levicar N, Nutall RK, Lah TT (2003) Proteases in brain tumour progression. Acta Neurochir 145:825–838. doi:10.1007/s00701-003-0097-z CrossRef

20.

Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR (1984) Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 38:745–755. doi:10.1016/0092-8674(84)90270-8 PubMedCrossRef

21.

Kelly J, Gilbert C, Stark G, Kerr I (1985) Differential regulation of interferon-induced mRNAs and c-myc mRNA by alpha- and gamma-interferons. Eur J Biochem 153:367–371. doi:10.1111/j.1432-1033.1985.tb09312.x PubMedCrossRef

22.

Evans S, Lee D, Han T, Tomasi T, Evans R (1990) Monoclonal antibody to the interferon-inducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemic B cells. Blood 76:2583–2593PubMed

23.

Deblandre GA, Marinx OP, Evans SS, Majjaj S, Leo O, Caput D, Huez GA, Wathelet MG (1995) Expression cloning of an interferon-inducible 17-KDa membrane-protein implicated in the control of cell-growth. J Biol Chem 270:23860–23866. doi:10.1074/jbc.270.40.23860 PubMedCrossRef

24.

Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848. doi:10.1038/nri1961 PubMedCrossRef

25.

Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11–22. doi:10.1038/nrc1252 PubMedCrossRef

Title: Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells
Authors: Fang Yu
Samuel S. M. Ng
Billy K. C. Chow
Johnny Sze
Gang Lu
Wai Sang Poon
Hsiang-Fu Kung
Marie C. M. Lin
Publication date: 01-06-2011
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2011
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0377-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas

Characterization of signaling function and expression of HLA class I molecules in medulloblastoma

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas

Links between private habits, psychological stress and brain cancer: a case–control pilot study in France

Clinical significance of thallium-201 SPECT after postoperative radiotherapy in patients with glioblastoma multiforme

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide